News Sentiment

DYN sentiment intelligence

Dyne Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 55 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 23.42 Week of 10 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

85/100 classification confidence.

Company focus 47

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+1.5% over one week, +28.8% over four weeks, trend active, and near fair-value range.

Latest direct headline Neutral

Dyne Therapeutics (DYN) Inspires Confidence With Its Force Platform

Market Reaction

Balanced read

61/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 85/100 classification
One-week reaction 1.5% Price digesting
Trend fit Trend active 28.8% over four weeks
Fair value 19.4% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 33
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 47
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 8
Stock Titan 8
TradingView 6
simplywall.st 5
Investing.com 4
Investing.com Canada 3
MT Newswires 3
GlobeNewswire 3

Event Lens

What the news is about

Classified themes
Market update 38
Earnings 11
Analyst action 3
Deals and strategy 1
Regulatory and legal 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 55
Stock Titan Direct company coverage

Dyne Therapeutics (DYN) director-linked Atlas funds sell 777K shares under 10b5-1 plan

Venture funds affiliated with Dyne Therapeutics (DYN) director Jason P. Rhodes sold a combined total of 777,451 shares of common stock on July 6-7, 2026, under a Rule 10b5-1 trading plan. The sales occurred at weighted-average prices between $22.79 and $23.62 per share. Despite t

Tone
Negative 30/100
Event
Market update
Published
09 Jul 2026 02:11
Source
Stock Titan
Investing.com Direct company coverage

Dyne therapeutics director Jason Rhodes sells $17.86 million in stock

Dyne Therapeutics director Jason P. Rhodes sold approximately $17.86 million worth of company stock through various Atlas Venture funds on July 6 and 7, 2026. These sales, executed via a Rule 10b5-1 trading plan, occurred while the stock was trading near its 52-week high after a

Tone
Negative 33/100
Event
Market update
Published
09 Jul 2026 00:11
Source
Investing.com
Investing.com Nigeria Direct company coverage

Form 4 Dyne Therapeutics Inc For: 8 July By Investing.com

This article announces that Dyne Therapeutics Inc. filed a Form 4 for July 8th. The filing is a standard disclosure related to insider trading, though no specific details of the transaction are provided in this brief announcement. The article is very short and predominantly featu

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 22:44
Source
Investing.com Nigeria
Stock Titan Direct company coverage

[144] Dyne Therapeutics, Inc. SEC Filing

This article reports on Dyne Therapeutics, Inc.'s SEC Form 144 filing, which indicates a proposed sale of securities. The filing details include the type of securities, the number of shares to be sold, their aggregate market value, and the acquisition transaction details. The com

Tone
Neutral 50/100
Event
Deals and strategy
Published
07 Jul 2026 21:09
Source
Stock Titan
Stock Traders Daily Direct company coverage

(DYN) Movement Within Algorithmic Entry Frameworks

This article analyzes Dyne Therapeutics Inc. (NYSE: DYN) based on algorithmic entry frameworks, highlighting strong sentiment across all time horizons. It provides three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target,

Tone
Positive 66/100
Event
Analyst action
Published
06 Jul 2026 23:46
Source
Stock Traders Daily
Simply Wall Street Direct company coverage

Will Barry Greene’s Board Role Shape Dyne Therapeutics’ (DYN) Path From Platform to Products?

Dyne Therapeutics has appointed biopharma veteran Barry E. Greene to its Board of Directors. Greene's extensive experience in commercializing complex therapies for rare diseases could bolster investor confidence in Dyne's ability to translate its FORCE platform programs, like z-r

Tone
Positive 63/100
Event
Market update
Published
05 Jul 2026 13:46
Source
Simply Wall Street
eToro Direct company coverage

Dyne Therapeutics Inc (DYN) Stock Price | Analyst Target 40.13 & Strong Buy Consensus

Analysts have set a strong buy consensus and a price target of $40.13 for Dyne Therapeutics Inc (DYN). The stock is currently trading at $23.07, reflecting an increase of 5.87% in the last 24 hours. Dyne Therapeutics, a biotechnology company, focuses on developing therapies for s

Tone
Positive 76/100
Event
Analyst action
Published
04 Jul 2026 13:12
Source
eToro
The Motley Fool Direct company coverage

Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?

This article compares Dyne Therapeutics and Recursion Pharmaceuticals, two development-stage biopharma companies, to determine which is a better investment in 2026. Dyne focuses on targeted therapies for neuromuscular diseases and is closer to market entry with its first product,

Tone
Positive 64/100
Event
Market update
Published
04 Jul 2026 09:21
Source
The Motley Fool
TradingView Direct company coverage

Price to book forward of Dyne Therapeutics, Inc. – NASDAQ:DYN

This article displays the "Price to book forward" metric for Dyne Therapeutics, Inc. (NASDAQ: DYN) on TradingView. It provides a quick financial overview for the company, accessible through the platform's various financial analysis tools. The page highlights that the market is cu

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 05:09
Source
TradingView
Investing.com Direct company coverage

Dyne therapeutics director Jason Rhodes sells $10.7m in stock

Jason P Rhodes, a director at Dyne Therapeutics, Inc. (NASDAQ:DYN), sold over 504,000 shares of the company's common stock for approximately $10.7 million across two transactions in late June 2026, executed via a Rule 10b5-1 trading plan. Despite the sale, the stock has shown a s

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 12:39
Source
Investing.com
Investing.com Canada Direct company coverage

Form 4 Dyne Therapeutics Inc For: 30 June By Investing.com

This article from Investing.com reports on a Form 4 filing for Dyne Therapeutics Inc. for the period ending June 30. It includes the company's stock symbol DYN, which saw a 4.47% increase, and is dated June 30, 2026, at 07:14 p.m.

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 07:10
Source
Investing.com Canada
Stock Titan Direct company coverage

Atlas funds linked to Dyne (DYN) director sell 504,695 shares

Funds associated with Dyne Therapeutics director Jason P. Rhodes sold 504,695 shares of common stock in open-market transactions on June 26 and June 29, 2026. The sales were executed through Atlas Venture funds at weighted-average prices between $21.14 and $21.28, under a pre-est

Tone
Negative 28/100
Event
Market update
Published
30 Jun 2026 23:10
Source
Stock Titan
Barchart.com Direct company coverage

Myotonic Dystrophy Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Dyne Therapeutics, Avidity Biosciences, Harmony Biosciences, AMO Pharma, Lupin, AMO Pharma

DelveInsight's report highlights that over 20 companies are actively developing more than 22 Myotonic Dystrophy therapies, covering various clinical development stages from pre-clinical to marketed phases. Key emerging therapies include EF-210, ARO-DM1, VX-670, PGN-EDODM1, and DY

Tone
Positive 65/100
Event
Market update
Published
30 Jun 2026 08:09
Source
Barchart.com
Stock Titan Direct company coverage

Dyne Therapeutics, Inc. SEC Filing

This article reports on a Form 144 SEC filing by Dyne Therapeutics, Inc. (DYN) on June 29, 2026. The filing indicates a proposed sale of securities, specifically 40,702 shares of common stock acquired via private placement in 2020 by the issuer, with Merrill Lynch as the broker.

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 00:40
Source
Stock Titan
Investing.com Direct company coverage

Dyne therapeutics director Jason P Rhodes sells $5.65m in stock

Jason P Rhodes, a director at Dyne Therapeutics, Inc. (NASDAQ:DYN), recently sold 267,760 shares of the company’s common stock for approximately $5.65 million through a Rule 10b5-1 trading plan. These transactions took place between June 23 and June 25, 2026, with prices ranging

Tone
Negative 40/100
Event
Market update
Published
27 Jun 2026 10:11
Source
Investing.com
TradingView Direct company coverage

Price to earnings forward of Dyne Therapeutics Inc – BX:DYN

This page provides financial data specifically on the "Price to earnings forward" for Dyne Therapeutics Inc (BX:DYN). The content indicates the market is closed, with no current trades. It also highlights that financial and reference data are provided by ICE Data Services and Fac

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 09:42
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Dyne Therapeutics, Inc. – NASDAQ:DYN

This article provides the "Price to sales forward" financial metric for Dyne Therapeutics, Inc. (NASDAQ: DYN). It indicates that the period value is available and notes that the market was closed at the time of publication, showing no trades.

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 06:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Dyne Therapeutics Inc – BX:DYN

This article provides forward-looking enterprise value to EBIT data for Dyne Therapeutics Inc (BX:DYN) on TradingView. It appears to be a financial data snippet from a larger platform, showing market status and financial figures.

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 03:41
Source
TradingView
Investing.com Direct company coverage

Dyne Therapeutics stock initiated at buy by TD Cowen on platform

TD Cowen has initiated coverage on Dyne Therapeutics Inc. (NASDAQ:DYN) with a "buy" rating, citing the company's FORCE platform and late-stage clinical programs for neuromuscular and CNS diseases. The stock has seen a significant surge of 105% over the past year, reflecting inves

Tone
Positive 71/100
Event
Analyst action
Published
26 Jun 2026 22:09
Source
Investing.com
Stock Titan Direct company coverage

Dyne Therapeutics (NASDAQ: DYN) CFO sells 2,362 shares to cover taxes

Dyne Therapeutics' CFO, Lucera Erick, sold 2,362 shares of common stock at a weighted average price of $20.37 per share. This transaction was conducted to meet tax obligations arising from the vesting and settlement of restricted stock units. Following the sale, Erick retains ben

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 20:16
Source
Stock Titan
Moomoo Direct company coverage

Dyne Therapeutics(DYN.US) Director Sells US$5.65 Million in Common Stock

Dyne Therapeutics (DYN.US) Director, HOLLAND TIMOTHY, sold 160,000 shares of common stock at an average price of $35.33 per share, totaling $5.65 million. This transaction was reported on June 25, 2026.

Tone
Negative 29/100
Event
Market update
Published
26 Jun 2026 15:41
Source
Moomoo
Investing.com Canada Direct company coverage

Form 4 Dyne Therapeutics Inc For: 26 June By Investing.com

Investing.com reports on a Form 4 filing for Dyne Therapeutics Inc. which occurred on June 26. This brief article primarily serves as an announcement for the regulatory filing related to the company. The specific details of the Form 4 are not provided within the article text.

Tone
Neutral 50/100
Event
Regulatory and legal
Published
26 Jun 2026 12:41
Source
Investing.com Canada
Stock Titan Direct company coverage

Dyne Therapeutics (DYN) director-linked funds sell 267,760 shares

Funds affiliated with Dyne Therapeutics (DYN) director Jason P. Rhodes sold a total of 267,760 shares of common stock between June 23 and June 25, 2026. These open-market sales were executed at weighted average prices around $21 per share, under a pre-arranged Rule 10b5-1 trading

Tone
Negative 18/100
Event
Market update
Published
26 Jun 2026 12:41
Source
Stock Titan